Metabolic Syndrome: Myth or Reality in the Endocrinology Clinic

The document from 2017 examines metabolic syndrome, a cluster of conditions including hypertension, dyslipidemia, hyperglycemia, and central obesity, which collectively heighten the risk of cardiovascular diseases and Type 2 diabetes. It acknowledges the syndrome's increasing prevalence due to lifestyle factors and obesity. The pathogenesis is linked to obesity, insulin resistance, inflammation, endothelial dysfunction, and a procoagulant state. Lifestyle interventions are the primary treatment, with pharmacotherapy as a secondary option when lifestyle changes prove inadequate. The document also explores the role of proinflammatory cytokines and natriuretic peptides in metabolic syndrome, suggesting new therapeutic targets. Large-scale studies, such as ALLHAT with over 40,000 participants, support the effectiveness of pharmacological treatments for the syndrome's components. Despite debates over the syndrome's validity, the document concludes that its individual metabolic issues are undeniable and must be addressed to mitigate the risks of diabetes and cardiovascular diseases.